Stifel Financial Corp Has $6.83 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Stifel Financial Corp grew its holdings in Exact Sciences Co. (NASDAQ:EXASFree Report) by 54.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,319 shares of the medical research company’s stock after purchasing an additional 32,425 shares during the period. Stifel Financial Corp owned approximately 0.05% of Exact Sciences worth $6,830,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wolff Wiese Magana LLC raised its position in Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after buying an additional 340 shares during the period. Valley National Advisers Inc. increased its holdings in shares of Exact Sciences by 29.5% in the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 176 shares during the period. National Bank of Canada FI lifted its position in shares of Exact Sciences by 30.9% in the fourth quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after purchasing an additional 200 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of Exact Sciences in the fourth quarter worth approximately $66,000. Finally, Desjardins Global Asset Management Inc. boosted its holdings in shares of Exact Sciences by 40.9% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 903 shares of the medical research company’s stock worth $67,000 after purchasing an additional 262 shares during the period. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Activity

In related news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the completion of the transaction, the chief executive officer now owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the sale, the executive vice president now owns 71,787 shares in the company, valued at $5,025,090. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,498 shares of company stock valued at $370,105. 1.36% of the stock is owned by insiders.

Exact Sciences Trading Down 3.9 %

Shares of EXAS stock opened at $42.93 on Friday. The business’s 50 day moving average is $58.89 and its two-hundred day moving average is $62.77. The company has a quick ratio of 1.45, a current ratio of 1.64 and a debt-to-equity ratio of 0.66. Exact Sciences Co. has a 12 month low of $42.72 and a 12 month high of $100.77. The company has a market cap of $7.92 billion, a PE ratio of -32.52 and a beta of 1.26.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). The business had revenue of $637.52 million for the quarter, compared to analyst estimates of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. Equities analysts predict that Exact Sciences Co. will post -1.15 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on EXAS. Jefferies Financial Group initiated coverage on shares of Exact Sciences in a research report on Monday, June 3rd. They issued a “buy” rating and a $75.00 target price for the company. TheStreet cut Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. BTIG Research cut their price target on Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Finally, Citigroup lowered their price target on Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and an average price target of $93.07.

Check Out Our Latest Research Report on Exact Sciences

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.